Know Cancer

or
forgot password

A Genome-Wide Scan for Quantitative Trait Loci of Hematocrit - A Framingham Study


N/A
N/A
N/A
Not Enrolling
Both
Vascular Diseases

Thank you

Trial Information

A Genome-Wide Scan for Quantitative Trait Loci of Hematocrit - A Framingham Study


Many studies have shown that hematocrit (HCT) levels are associated with cerebrovascular
disease, cardiovascular disease (CVD), peripheral vascular disease, as well as all-cause
mortality. Twin studies have shown that HCT variation is largely determined by genetic
factors with heritability estimated as 40% - 65%. So far, no linkage analysis in humans
between HCT and DNA markers have been reported. The purpose of this protocol is to identify
chromosome regions that contain quantitative trait loci (QTL) involved in controlling HCT
levels. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted
in 330 families. HCT was measured in the original cohort and Framingham offspring. These
data provide us the opportunity to undertake linkage analyses using variance component
method to map quantitative trait loci (QTL) of HCT.

Inclusion Criteria


- INCLUSION /EXCLUSION CRITERIA

The study population will include the members of the 330 Framingham Study families with
genome scan.

Type of Study:

Observational

Study Design:

N/A

Authority:

United States: Federal Government

Study ID:

030219

NCT ID:

NCT00062777

Start Date:

June 2003

Completion Date:

June 2011

Related Keywords:

  • Vascular Diseases
  • Genetics
  • Populations
  • CVD Risk
  • Gene Mapping
  • Epidemiology
  • Framingham Study
  • Vascular Diseases
  • Vascular Diseases

Name

Location

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892